Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Medicinal Chemistry: From Targets to Therapies.

Maryanoff BE, Wipf P.

ACS Med Chem Lett. 2019 Jul 11;10(7):1014. doi: 10.1021/acsmedchemlett.9b00244. eCollection 2019 Jul 11. No abstract available.

PMID:
31312399
2.

First-Time Disclosures of Clinical Candidates.

Maryanoff BE.

ACS Med Chem Lett. 2018 Jul 12;9(7):575. doi: 10.1021/acsmedchemlett.8b00207. eCollection 2018 Jul 12. No abstract available.

3.

Editorial on First-Time Disclosures of Clinical Candidates.

Maryanoff BE.

J Med Chem. 2018 Jul 12;61(13):5449. doi: 10.1021/acs.jmedchem.8b00739. Epub 2018 May 21. No abstract available.

PMID:
29782164
4.

Deuterated Drug Molecules: Focus on FDA-Approved DeutetrabenazinePublished as part of the Biochemistry series "Biochemistry to Bedside".

DeWitt SH, Maryanoff BE.

Biochemistry. 2018 Feb 6;57(5):472-473. doi: 10.1021/acs.biochem.7b00765. Epub 2017 Nov 21. No abstract available.

PMID:
29160059
5.

Self-Assembling Cyclic d,l-α-Peptides as Modulators of Plasma HDL Function. A Supramolecular Approach toward Antiatherosclerotic Agents.

Zhao Y, Leman LJ, Search DJ, Garcia RA, Gordon DA, Maryanoff BE, Ghadiri MR.

ACS Cent Sci. 2017 Jun 28;3(6):639-646. doi: 10.1021/acscentsci.7b00154. Epub 2017 Jun 13.

6.

Phenotypic Assessment and the Discovery of Topiramate.

Maryanoff BE.

ACS Med Chem Lett. 2016 Jun 13;7(7):662-5. doi: 10.1021/acsmedchemlett.6b00176. eCollection 2016 Jul 14.

7.

Our scope expansion to include biologics.

Maryanoff BE, Huryn DM.

ACS Med Chem Lett. 2015 Mar 12;6(3):227. doi: 10.1021/acsmedchemlett.5b00063. eCollection 2015 Mar 12. No abstract available.

8.

In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I.

Zhao Y, Black AS, Bonnet DJ, Maryanoff BE, Curtiss LK, Leman LJ, Ghadiri MR.

J Lipid Res. 2014 Oct;55(10):2053-63. doi: 10.1194/jlr.M049262. Epub 2014 Jun 29.

9.

Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).

McComsey DF, Smith-Swintosky VL, Parker MH, Brenneman DE, Malatynska E, White HS, Klein BD, Wilcox KS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N, Reitz AB, Maryanoff BE.

J Med Chem. 2013 Nov 27;56(22):9019-30. doi: 10.1021/jm400894u. Epub 2013 Nov 11.

10.

Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.

Leman LJ, Maryanoff BE, Ghadiri MR.

J Med Chem. 2014 Mar 27;57(6):2169-96. doi: 10.1021/jm4005847. Epub 2013 Oct 29. Review.

11.

Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs.

Zhao Y, Imura T, Leman LJ, Curtiss LK, Maryanoff BE, Ghadiri MR.

J Am Chem Soc. 2013 Sep 11;135(36):13414-24. doi: 10.1021/ja404714a. Epub 2013 Aug 26.

12.

Pyrimidinopyrimidine inhibitors of ketohexokinase: exploring the ring C2 group that interacts with Asp-27B in the ligand binding pocket.

Maryanoff BE, O'Neill JC, McComsey DF, Yabut SC, Luci DK, Gibbs AC, Connelly MA.

Bioorg Med Chem Lett. 2012 Aug 15;22(16):5326-9. doi: 10.1016/j.bmcl.2012.06.008. Epub 2012 Jun 17.

PMID:
22795331
13.

Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.

Hutt DM, Olsen CA, Vickers CJ, Herman D, Chalfant M, Montero A, Leman LJ, Burkle R, Maryanoff BE, Balch WE, Ghadiri MR.

ACS Med Chem Lett. 2011 Jul 21;2(9):703-707.

14.

Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site.

Maryanoff BE, O'Neill JC, McComsey DF, Yabut SC, Luci DK, Jordan AD Jr, Masucci JA, Jones WJ, Abad MC, Gibbs AC, Petrounia I.

ACS Med Chem Lett. 2011 Apr 18;2(7):538-43. doi: 10.1021/ml200070g. eCollection 2011 Jul 14. Erratum in: ACS Med Chem Lett. 2012 Mar 8;3(3):263.

15.

Potency variation of small-molecule chymase inhibitors across species.

Kervinen J, Crysler C, Bayoumy S, Abad MC, Spurlino J, Deckman I, Greco MN, Maryanoff BE, de Garavilla L.

Biochem Pharmacol. 2010 Oct 1;80(7):1033-41. doi: 10.1016/j.bcp.2010.06.014. Epub 2010 Jun 23.

PMID:
20599788
16.

Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.

Lu T, Markotan T, Ballentine SK, Giardino EC, Spurlino J, Crysler CS, Brown K, Maryanoff BE, Tomczuk BE, Damiano BP, Shukla U, End D, Andrade-Gordon P, Bone RF, Player MR.

J Med Chem. 2010 Feb 25;53(4):1843-56. doi: 10.1021/jm901802n. Erratum in: J Med Chem. 2010 Apr 22;53(8):3422. Crysler, Carl S [added].

PMID:
20102150
17.

Urotensin-II receptor modulators as potential drugs.

Maryanoff BE, Kinney WA.

J Med Chem. 2010 Apr 8;53(7):2695-708. doi: 10.1021/jm901294u. Review. No abstract available.

PMID:
20043680
18.

Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa.

Giardino EC, Haertlein BJ, de Garavilla L, Costanzo MJ, Damiano BP, Andrade-Gordon P, Maryanoff BE.

Blood Coagul Fibrinolysis. 2010 Mar;21(2):128-34. doi: 10.1097/MBC.0b013e3283358100.

PMID:
20010091
19.

Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation.

Maryanoff BE, de Garavilla L, Greco MN, Haertlein BJ, Wells GI, Andrade-Gordon P, Abraham WM.

Am J Respir Crit Care Med. 2010 Feb 1;181(3):247-53. doi: 10.1164/rccm.200904-0627OC. Epub 2009 Oct 29.

PMID:
19875688
20.
21.

Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits.

Lawson EC, Luci DK, Ghosh S, Kinney WA, Reynolds CH, Qi J, Smith CE, Wang Y, Minor LK, Haertlein BJ, Parry TJ, Damiano BP, Maryanoff BE.

J Med Chem. 2009 Dec 10;52(23):7432-45. doi: 10.1021/jm900683d.

PMID:
19731961
22.

Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies.

Parker MH, Smith-Swintosky VL, McComsey DF, Huang Y, Brenneman D, Klein B, Malatynska E, White HS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N, Iannucci R, Leclercq L, Cuyckens F, Reitz AB, Maryanoff BE.

J Med Chem. 2009 Dec 10;52(23):7528-36. doi: 10.1021/jm801432r.

PMID:
19388676
23.

2009 Edward E Smissman Award. Pharmaceutical "gold" from neurostabilizing agents: topiramate and successor molecules.

Maryanoff BE.

J Med Chem. 2009 Jun 11;52(11):3431-40. doi: 10.1021/jm900141j. No abstract available.

PMID:
19385640
24.

Drug discovery and the medicinal chemist.

Maryanoff BE.

Future Med Chem. 2009 Apr;1(1):11-5. doi: 10.4155/fmc.09.2. No abstract available.

25.

Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.

Gunnet JW, Wines P, Xiang M, Rybczynski P, Andrade-Gordon P, de Garavilla L, Parry TJ, Cheung WM, Minor L, Demarest KT, Maryanoff BE, Damiano BP.

Eur J Pharmacol. 2008 Aug 20;590(1-3):333-42. doi: 10.1016/j.ejphar.2008.06.010. Epub 2008 Jun 7.

PMID:
18599033
26.

Thrombogenic collagen-mimetic peptides: Self-assembly of triple helix-based fibrils driven by hydrophobic interactions.

Cejas MA, Kinney WA, Chen C, Vinter JG, Almond HR Jr, Balss KM, Maryanoff CA, Schmidt U, Breslav M, Mahan A, Lacy E, Maryanoff BE.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8513-8. doi: 10.1073/pnas.0800291105. Epub 2008 Jun 16.

27.

In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor.

Aluisio L, Lord B, Barbier AJ, Fraser IC, Wilson SJ, Boggs J, Dvorak LK, Letavic MA, Maryanoff BE, Carruthers NI, Bonaventure P, Lovenberg TW.

Eur J Pharmacol. 2008 Jun 10;587(1-3):141-6. doi: 10.1016/j.ejphar.2008.04.008. Epub 2008 Apr 10.

PMID:
18499098
28.

Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Shank RP, Maryanoff BE.

CNS Neurosci Ther. 2008 Summer;14(2):120-42. doi: 10.1111/j.1527-3458.2008.00041.x. Review.

29.

Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif.

Kreutter KD, Lu T, Lee L, Giardino EC, Patel S, Huang H, Xu G, Fitzgerald M, Haertlein BJ, Mohan V, Crysler C, Eisennagel S, Dasgupta M, McMillan M, Spurlino JC, Huebert ND, Maryanoff BE, Tomczuk BE, Damiano BP, Player MR.

Bioorg Med Chem Lett. 2008 May 1;18(9):2865-70. doi: 10.1016/j.bmcl.2008.03.087. Epub 2008 Apr 8.

PMID:
18420408
30.

Carbonic anhydrase-II inhibition. what are the true enzyme-inhibitory properties of the sulfamide cognate of topiramate?

Maryanoff BE, McComsey DF, Lee J, Smith-Swintosky VL, Wang Y, Minor LK, Todd MJ.

J Med Chem. 2008 Apr 24;51(8):2518-21. doi: 10.1021/jm7015649. Epub 2008 Mar 26.

PMID:
18363349
31.

Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate.

Shank RP, Smith-Swintosky VL, Maryanoff BE.

J Enzyme Inhib Med Chem. 2008 Apr;23(2):271-6. doi: 10.1080/14756360701507001 .

PMID:
18343915
32.

Suzuki-Miyaura approach to JNJ-26076713, an orally active tetrahydroquinoline-containing alphaVbeta3/alphaVbeta5 integrin antagonist. enantioselective synthesis and stereochemical studies.

Kinney WA, Teleha CA, Thompson AS, Newport M, Hansen R, Ballentine S, Ghosh S, Mahan A, Grasa G, Zanotti-Gerosa A, Dingenen J, Schubert C, Zhou Y, Leo GC, McComsey DF, Santulli RJ, Maryanoff BE.

J Org Chem. 2008 Mar 21;73(6):2302-10. doi: 10.1021/jo702551t. Epub 2008 Feb 16.

PMID:
18278942
33.

Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives.

Costanzo MJ, Yabut SC, Zhang HC, White KB, de Garavilla L, Wang Y, Minor LK, Tounge BA, Barnakov AN, Lewandowski F, Milligan C, Spurlino JC, Abraham WM, Boswell-Smith V, Page CP, Maryanoff BE.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2114-21. doi: 10.1016/j.bmcl.2008.01.093. Epub 2008 Jan 30.

PMID:
18272363
34.

Carba-nucleosides as potent antagonists of the adenosine 5'-diphosphate (ADP) purinergic receptor (P2Y12 on human platelets.

Ye H, Chen C, Zhang HC, Haertlein B, Parry TJ, Damiano BP, Maryanoff BE.

ChemMedChem. 2008 May;3(5):732-6. doi: 10.1002/cmdc.200700310. No abstract available.

PMID:
18224705
35.

7-fluoroindazoles as potent and selective inhibitors of factor Xa.

Lee YK, Parks DJ, Lu T, Thieu TV, Markotan T, Pan W, McComsey DF, Milkiewicz KL, Crysler CS, Ninan N, Abad MC, Giardino EC, Maryanoff BE, Damiano BP, Player MR.

J Med Chem. 2008 Jan 24;51(2):282-97. Epub 2007 Dec 27.

PMID:
18159923
36.

Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.

Santulli RJ, Kinney WA, Ghosh S, Decorte BL, Liu L, Tuman RW, Zhou Z, Huebert N, Bursell SE, Clermont AC, Grant MB, Shaw LC, Mousa SA, Galemmo RA Jr, Johnson DL, Maryanoff BE, Damiano BP.

J Pharmacol Exp Ther. 2008 Mar;324(3):894-901. Epub 2007 Dec 14.

PMID:
18083913
37.

Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.

Maryanoff BE, Costanzo MJ.

Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. Epub 2007 Nov 6. Review.

PMID:
18053726
38.

Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.

Xiang MA, Rybczynski PJ, Patel M, Chen RH, McComsey DF, Zhang HC, Gunnet JW, Look R, Wang Y, Minor LK, Zhong HM, Villani FJ, Demarest KT, Damiano BP, Maryanoff BE.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6623-8. Epub 2007 Sep 19.

PMID:
17942308
39.

Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment.

Luci DK, Ghosh S, Smith CE, Qi J, Wang Y, Haertlein B, Parry TJ, Li J, Almond HR Jr, Minor LK, Damiano BP, Kinney WA, Maryanoff BE, Lawson EC.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6489-92. Epub 2007 Oct 1.

PMID:
17933531
40.

Nanoparticles that display short collagen-related peptides. Potent stimulation of human platelet aggregation by triple helical motifs.

Cejas MA, Chen C, Kinney WA, Maryanoff BE.

Bioconjug Chem. 2007 Jul-Aug;18(4):1025-7. Epub 2007 Jun 21.

PMID:
17583929
41.

Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.

Greco MN, Hawkins MJ, Powell ET, Almond HR Jr, de Garavilla L, Hall J, Minor LK, Wang Y, Corcoran TW, Di Cera E, Cantwell AM, Savvides SN, Damiano BP, Maryanoff BE.

J Med Chem. 2007 Apr 19;50(8):1727-30. Epub 2007 Mar 16.

PMID:
17361995
42.

Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.

Zhang HC, Boñaga LV, Ye H, Derian CK, Damiano BP, Maryanoff BE.

Bioorg Med Chem Lett. 2007 May 15;17(10):2863-8. Epub 2007 Feb 25.

PMID:
17350261
43.

Collagen-related peptides: self-assembly of short, single strands into a functional biomaterial of micrometer scale.

Cejas MA, Kinney WA, Chen C, Leo GC, Tounge BA, Vinter JG, Joshi PP, Maryanoff BE.

J Am Chem Soc. 2007 Feb 28;129(8):2202-3. Epub 2007 Feb 2. No abstract available.

PMID:
17269769
44.
45.
46.

Exploration of potential prodrugs of RWJ-445167, an oxyguanidine-based dual inhibitor of thrombin and factor Xa.

Maryanoff BE, McComsey DF, Costanzo MJ, Yabut SC, Lu T, Player MR, Giardino EC, Damiano BP.

Chem Biol Drug Des. 2006 Jul;68(1):29-36.

PMID:
16923023
47.

Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements.

Klinger AL, McComsey DF, Smith-Swintosky V, Shank RP, Maryanoff BE.

J Med Chem. 2006 Jun 15;49(12):3496-500.

PMID:
16759092
48.

Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.

Gong Y, Barbay JK, Dyatkin AB, Miskowski TA, Kimball ES, Prouty SM, Fisher MC, Santulli RJ, Schneider CR, Wallace NH, Ballentine SA, Hageman WE, Masucci JA, Maryanoff BE, Damiano BP, Andrade-Gordon P, Hlasta DJ, Hornby PJ, He W.

J Med Chem. 2006 Jun 1;49(11):3402-11.

PMID:
16722660
49.

Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.

Gunnet JW, Matthews JM, Maryanoff BE, de Garavilla L, Andrade-Gordon P, Damiano B, Hageman W, Look R, Stahle P, Streeter AJ, Wines PG, Demarest KT.

Clin Exp Pharmacol Physiol. 2006 Apr;33(4):320-6.

PMID:
16620295
50.

Selection of a 2-azabicyclo[2.2.2]octane-based alpha4beta1 integrin antagonist as an inhaled anti-asthmatic agent.

Lawson EC, Santulli RJ, Dyatkin AB, Ballentine SA, Abraham WM, Rudman S, Page CP, de Garavilla L, Damiano BP, Kinney WA, Maryanoff BE.

Bioorg Med Chem. 2006 Jun 15;14(12):4208-16. Epub 2006 Feb 21.

PMID:
16495061

Supplemental Content

Loading ...
Support Center